Although the scFv, intracellular costimulatory signals, delivery system, preconditioning regiments and doses were different in these two studies, both of them showed remarkable efficacy in CD30+ patients with chemotherapy-resistant HL and ALCL17,18. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.